Coinbase' stock tumbles on SEC warning, while First Republic and Regeneron shares rally, and other stocks on the moveMarket Watch • 03/23/23
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trialGlobeNewsWire • 03/23/23
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal TrialGlobeNewsWire • 03/23/23
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitisGlobeNewsWire • 03/21/23
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic DermatitisGlobeNewsWire • 03/21/23
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitisGlobeNewsWire • 03/18/23
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot DermatitisGlobeNewsWire • 03/18/23
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)Seeking Alpha • 03/15/23
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart DiseasePRNewsWire • 03/15/23
Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare ConferenceSeeking Alpha • 03/13/23
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA reviewGlobeNewsWire • 03/07/23
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA ReviewGlobeNewsWire • 03/07/23
Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript)Seeking Alpha • 03/06/23
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia RheumaticaGlobeNewsWire • 03/01/23
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)GlobeNewsWire • 02/24/23